CD274 and neoplasm: In addition, a bifunctional fusion protein M7824 (Bintrafuspalfa) was developed against PD-L1 and TGF-β, which can improve anti-tumor therapeutic effects by antagonizing PD-L1 and “trapping” TGFβ (32, 33).